Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of D-0120 and Allopurinol in Healthy Adults
NCT05360628Phase 1Completed
- Sponsor
- InventisBio
- Start
- Nov 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of darbinurad in hyperuricemia and gout (2 arms), sponsored by InventisBio. Primary endpoints: Type, incidence, severity and attribution of Adverse Events at 14 days and Plasma concentration of D-0120 and Allopurinol at 14 days. Started Nov 2021; status: completed.
02
Drugs
darbinurad
03
Conditions
hyperuricemiagout
Beyond the preview
Go deeper on NCT05360628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05360628.